Key Highlights

  • Total cash decreased $17.3 million, or 15 percent, since December 31, 2025.
  • Collaboration Revenue fell by a net $1.6 million, mainly under the Astellas agreement.
  • Cost of revenues was $1.9 million, compared with $1.6 million a year earlier.
  • Gyre describes itself as a U.S. biopharmaceutical company with research and commercial operations in China.

Gyre Therapeutics, Inc. (NASDAQ:GYRE), a U.S. biopharmaceutical company with research operations and a commercial Business in China, reported third quarter 2026 results and a business update. Chief Executive Dr. Ying Luo said the company was pleased with its execution during the quarter. Total cash fell $17.3 million, or 15 percent, from $116.1 million at December 31, 2025, primarily because short-term investments declined by $15.5 million.

Cash Movement

The decline in short-term investments accounts for most of the drop in total cash. Because the release describes the reduction as primarily a shift within the Investment portfolio, the change does not on its own indicate a spending increase of the same size, though the full Cash Flow Statement would be needed to confirm the net effect.

Total cash therefore stands at roughly $98.8 million, calculated from the reported figures. That balance is the base against which the company's development and commercial spending will be measured in the coming periods.

Collaboration Revenue and Costs

Collaboration revenue declined by a net $1.6 million, mainly driven by the Collaboration, Option, and License Agreement with Astellas Pharma. Collaboration income depends on milestone and partner activity, so changes in partner timing can move reported revenue materially from one period to the next.

The increase in cost against lower collaboration revenue narrows the Margin on that activity.

Sector Context and What to Watch

Protein degrader developers commonly rely on partnerships to fund development, which makes partner milestone timing important to a company's cash profile. Companies with operations in China also face regulatory and commercial considerations specific to that market.

Final Takeaways

Gyre's third quarter shows a 15 percent decline in total cash, lower collaboration revenue and higher cost of revenues. The company's funding depends on partner activity and on its spending decisions. The next quarterly disclosures will indicate whether the cash balance stabilizes and how collaboration income develops.